Olanzapine in the Treatment of Hair Pulling (Trichotillomania)

Learn more about:
Related Clinical Trial
Technology Assisted Treatment for Trichotillomania Leveraging Technological Advancements to Improve the Treatment of Trichotillomania Internet CBT for Trichotillomania and Skin Picking Disorder Developing Effective Response Inhibition Training for Symptom Relief in OCD and Trichotillomania Evaluation and Follow-up of Individuals With Obsessive-Compulsive Disorder and Related Conditions Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals Evaluation of a Brief Surf the Urge Intervention Feasibility Study for Treating Trichotillomania With Wearable Device and App System Cognitive Behavioral Treatment of Pediatric Trichotillomania Telepsychotherapy for the Treatment of Adolescents With Trichotillomania Stepped Care in the Treatment of Trichotillomania Response Inhibition Training for Individuals With Trichotillomania Cognitive Behavioral Therapy for Trichotillomania Examining Behavior Therapy for Trichotillomania in Children and Adolescents Comprehensive Behavioral (ComB) Model of Treatment for Trichotillomania Methylphenidate in ADHD With Trichotillomania Marinol in Trichotillomania or Obsessive Compulsive Disorder Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors Cognitive Training in Patients With Trichotillomania (Hair-pulling Disorder) Olanzapine in the Treatment of Hair Pulling (Trichotillomania) A Study in Patients With Trichotillomania Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania Inositol in Trichotillomania Trial of Aripiprazole in Trichotillomania Habit Reversal Training for Children and Adolescents With Trichotillomania Naltrexone in the Treatment of Trichotillomania N-Acetylcysteine for Pediatric Trichotillomania Online Response Inhibition Training for Trichotillomania N-Acetyl Cysteine in Trichotillomania Trichotillomania: Group Cognitive-Behavioral Therapy Efficacy of COMB (Comprehensive Behavioral) Model of Treatment of Trichotillomania Milk Thistle in Trichotillomania in Children and Adults Cognitive Behavioral Group Therapy for Trichotillomania (Hair Pulling Disorder) Testing a New Therapy for Trichotillomania Online Treatment of Trichotillomania

Brief Title

Olanzapine in the Treatment of Hair Pulling (Trichotillomania)

Official Title

A 12-Week, Double-Blind Trial of Olanzapine and Placebo in the Treatment of Trichotillomania

Brief Summary

      Trichotillomania (TTM) or hair-pulling has been considered as part of the obsessive
      compulsive disorder (OCD) spectrum, although treatment with OCD medications has largely been
      unsuccessful. Tics/Tourrettes' Syndrome (TS) is a disorder, which appears to be related to
      TTM, but is treated with a different class of medications than used in OCD, namely
      antipsychotics such as olanzapine. This is a study of the safety and efficacy of olanzapine
      in the treatment of hair pulling.

Study Phase

Phase 4

Study Type


Primary Outcome

Clinical Global Impression (CGI)-Improvement Scale ≤ 2

Secondary Outcome

 CGI-Severity Scale, Mean change from baseline in: Yale-Brown Obsessive Compulsive Scale for TTM, the Massachusetts General Hospital Hair Pulling Scale






* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

June 2000

Completion Date

March 2006

Eligibility Criteria

        Inclusion Criteria:

          -  primary DSM-IV trichotillomania; CGI-Severity ≥ 4

        Exclusion Criteria:

          -  Any other Axis I primary diagnosis; CGI-S < 4; current comorbid: OCD, MDD, alcohol or
             substance abuse; lifetime hx of: schizophrenia, bipolar affective disorder or
             dementia; current pregnancy/lactation; current suicidality or homicidality; major
             medical problems or clinically unstable medical disease; hx of: seizures, stroke or
             head trauma; prior use of neuroleptics




18 Years - 65 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


Michael A Van Ameringen, MD, FRCPC, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Study Sponsor

Hamilton Health Sciences Corporation


 Eli Lilly and Company

Study Sponsor

Michael A Van Ameringen, MD, FRCPC, Principal Investigator, Hamilton Health Science, McMaster Univeristy Medical Centre

Verification Date

March 2006